Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type 2 diabetes

The results of a phase IIa clinical trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate a rapid reduction in albuminuria and hyperuricaemia in patients with type II diabetes with combined treatment of verinurad and febuxostat.

The primary endpoint of the study was met; results reveal a 39% reduction in -to-creatinine ratio (UACR) after 12 weeks with combined of verinurad 9mg and febuxostat 80mg versus placebo (p=0.07). The study also shows a 57% reduction in urate (sUA) in the treatment group versus a 7% increase in the (p<0.0001) at 12 weeks. This effect was sustained at 24 weeks with a 62% reduction versus a 5% increase (p<0.0001). The effect on sUA was likely underestimated due to sample collection scheduling. The study also measured estimated glomerular filtration rate (eGFR) but the changes were insignificant.

"Although these are early clinical findings in a limited group of patients, our results show that combined treatment with verinurad and febuxostat in patients with diabetes results in a rapid reduction in hyperuricaemia and albuminuria sustained through week 24," said Robert Terkeltaub, MD, Professor of Medicine, University of California San Diego, USA. "Further studies are planned to confirm the efficacy of urate lowering strategies combining verinurad and xanthine oxidase inhibitors in slowing progression of chronic kidney disease."

Verinurad is an inhibitor of the uric acid transporter (URAT1) and is currently under investigation for the treatment of hyperuricaemia and kidney disease. Febuxostat is a potent, selective xanthine oxidase inhibitor used to lower urate levels in patients with gout and hyperuricaemia. It is recommended in patients who do not reach target on, or are intolerant to, allopurinol. It is often used in patients with renal impairment since it is primarily metabolised in the liver.

"We welcome these positive results and look forward to the future clinical development of this novel urate-lowering treatment strategy, particularly in patients with hyperuricaemia and kidney disease," said Professor Hans Bijlsma, President, EULAR.

The trial included 60 with type II diabetes who had a sUA of 6.0mg/dL or above, eGFR of 30mL/min/1.73m2 or above, and UACR of 30-3500 mg/g. Patients were randomised to receive either verinurad 9mg and febuxostat 80mg (treatment group) or placebo. Patients were excluded if they had a history of gout or recent treatment with urate-lowering therapy which avoided the need to administer gout prophylaxis. Most adverse events were mild to moderate, those reported in more than one patient in the treatment group were diarrhoea, dizziness and nasopharyngitis, and only one gout flare-up was reported (in the treatment group).


Explore further

Gout drug reduces adverse events in patients with hyperuricaemia

More information: Terkeltaub R, Dronamraju N, Johansson SA, et al. Urate-Lowering Therapy With Verinurad And Febuxostat Reduces Serum Uric Acid And Albuminuria In Hyperuricemic Patients With Diabetes. EULAR 2019; Madrid: Abstract OP0207.
Citation: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type 2 diabetes (2019, June 13) retrieved 13 October 2019 from https://medicalxpress.com/news/2019-06-verinurad-febuxostat-significantly-albuminuria-hyperuricaemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more